[Click eStock] "Olix, Possibility of Pipeline Technology Transfer"

ResearchAlum analyzed on the 27th that Olix possesses pipelines including treatments for obesity, hair loss, and metabolic dysfunction-associated steatohepatitis (MASH) that attract interest from global pharmaceutical companies. They suggested a target stock price of 27,000 KRW.

Founded in 2010, Olix is a developer of RNA interference (RNAi)-based therapeutics. It has a platform that effectively delivers siRNA to targets, and its pipelines that have entered clinical stages include four types based on a local administration treatment development platform, such as hypertrophic scar treatment and hair loss treatment.

Researcher Kim Jaemu of ResearchAlum stated, "At the end of last year, a single administration of the dry and wet macular degeneration treatment (OLX301A) was completed, and a milestone payment was received from the French ophthalmology specialist company Th??." He added, "After multiple administrations are completed this year, an additional milestone payment exceeding 10 billion KRW will be received."

He continued, "An advance payment and milestone payments were also received from China's Hansoh Pharmaceutical," and analyzed, "Considering only the pipeline value and candidate discovery capability, the company is undervalued." He emphasized, "We also expect technology transfers for the hair loss treatment (OLX104C) currently in Phase 1 clinical trials and the hypertrophic scar treatment (OLX101A) that completed the US Phase 2a clinical trial and is awaiting the results report. The MASH and obesity treatments are the pipelines with the greatest technology transfer expectations."

Researcher Kim expressed optimism, saying, "If a meaningful contract is signed with a global pharmaceutical company, a positive stock price trend is expected."

He explained, "There are multiple upcoming momentum events, including resolving concerns about designation as a management item, FDA approval decision for the MASH treatment next month, and the launch of hair loss cosmetics in the second half of the year."